JERSEY CITY, N.J. — January 28, 2026 — Leads & Copy — SCYNEXIS, Inc. (NASDAQ: SCYX) has announced upcoming presentations highlighting data on its second-generation fungerp drug candidate, SCY-247, at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in Las Vegas, Nevada.
The inaugural IMARI meeting is taking place from January 28 to 30, 2026.
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS, stated that the company is pleased to participate in the meeting, which focuses on addressing the threat of antimicrobial resistance. Angulo also noted the in vitro and in vivo antifungal activity of SCY-247, along with its safety profile and pharmacokinetics observed in clinical investigations. According to Angulo, these factors position the drug candidate as a potentially critical weapon against deadly fungal infections, including those resistant to existing antifungal therapies. He added that the company looks forward to sharing its development progress with the scientific community at IMARI.
A presentation of SCY-247, highlighting its antifungal activity against resistant fungi, will be included in the Plenary session “New Antimicrobial Agents in The Pipeline: Early Clinical Development” on January 29 from 9-10:30am and will also be displayed in the Poster session on January 30th. The presentation and poster will be posted in the Publications and Presentations section of the Company’s website after the meeting.
IMARI is a joint conference organized by the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA) that brings together researchers, clinicians, industry leaders and policymakers to address antimicrobial resistance.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company focused on developing medicines to overcome and prevent difficult-to-treat infections. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. The second generation fungerp SCY-247 is currently in clinical stages of development and has received QIDP and Fast Track designation from the FDA. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phases.
Source: SCYNEXIS, Inc.
